Hepion Pharmaceuticals, Inc. (OTCQB: HEPA) is a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases. Through its subsidiary Gravitas Life Sciences, LLC, a clinical-stage biotechnology company, Hepion is advancing therapeutic candidates in immunology and inflammation, including a transmucosal buccal film of an established opioid antagonist and an oral formulation of a validated anti-inflammatory antibody. The Company’s diagnostic program is built on novel circulating tumor RNA technology, which reads actively expressed tumor transcripts for the early detection of hepatocellular carcinoma in high-risk cirrhotic patients, a cancer that is curable when found early.